R-Health

Belkins
R-Health delivers more effective care and a better patient experience – all at a lower cost. We partner with employers, insurance companies, and healthcare brokers to offer primary care that’s truly collaborative. We deliver value-based healthcare two ways: R-Health Accountable Care, our commercial ACO, and R-Health Direct Primary Care, our innovative membership-based model that provides members with the care they deserve.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap, SignalPath | February 24, 2021

news image

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More

PHARMACY MARKET

VIRPAX ANNOUNCES MMS019 MANUFACTURING AND SUPPLY AGREEMENT

Virpax Pharmaceuticals | August 27, 2021

news image

Virpax® Pharmaceuticals, Inc., a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement with Seqens provides for both the supply material for...

Read More

VIEWS AND ANALYSIS

CMIC AND LOKAVANT COLLABORATE TO DEPLOY MACHINE LEARNING-POWERED CLINICAL TRIAL INTELLIGENCE PLATFORM

CMIC | June 25, 2021

news image

CMIC Co., Ltd., a leading Japanese Contract Research Organization (CRO), and Lokavant, a leading clinical trial intelligence company, announced today that they have agreed to use Lokavant's predictive analytics capabilities to assist CMIC's clinical operations. This strategic collaboration, Lokavant Oversight, monitoring, and operational risk management platform, will be implemented throughout CMIC studies. CMIC was the first firm in Japan to provide CRO services, and the ...

Read More

GENSCRIPT LAUNCHES NEOANTIGEN SPECIFIC PEPTIDE SYNTHESIS SERVICE FOR PRECISION IMMUNO-ONCOLOGY THERAPEUTIC DEVELOPMENT

BioSpace: Biotech, | April 01, 2020

news image

GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 highly difficult neoantigen peptides for more than 50 of the world's leading immuno-oncology companies. Unlike traditional targets such as tumor-associated antigens, neoantigens are novel peptides on...

Read More

PHARMA TECH

Quantum Leap, SignalPath | February 24, 2021

news image

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More

PHARMACY MARKET

Virpax Pharmaceuticals | August 27, 2021

news image

VIRPAX ANNOUNCES MMS019 MANUFACTURING AND SUPPLY AGREEMENT

Virpax® Pharmaceuticals, Inc., a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement with Seqens provides for both the supply material for...

Read More

VIEWS AND ANALYSIS

CMIC | June 25, 2021

news image

CMIC AND LOKAVANT COLLABORATE TO DEPLOY MACHINE LEARNING-POWERED CLINICAL TRIAL INTELLIGENCE PLATFORM

CMIC Co., Ltd., a leading Japanese Contract Research Organization (CRO), and Lokavant, a leading clinical trial intelligence company, announced today that they have agreed to use Lokavant's predictive analytics capabilities to assist CMIC's clinical operations. This strategic collaboration, Lokavant Oversight, monitoring, and operational risk management platform, will be implemented throughout CMIC studies. CMIC was the first firm in Japan to provide CRO services, and the ...

Read More

BioSpace: Biotech, | April 01, 2020

news image

GENSCRIPT LAUNCHES NEOANTIGEN SPECIFIC PEPTIDE SYNTHESIS SERVICE FOR PRECISION IMMUNO-ONCOLOGY THERAPEUTIC DEVELOPMENT

GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 highly difficult neoantigen peptides for more than 50 of the world's leading immuno-oncology companies. Unlike traditional targets such as tumor-associated antigens, neoantigens are novel peptides on...

Read More